Gan & Lee Pharmaceuticals: Overweight trials

The registry lists 13 Overweight studies with Gan & Lee Pharmaceuticals as lead sponsor. 6 are open to participants now and 0 have results posted.

Phase 1 9Phase 2 3Phase 3 2(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Extension Study of the Phase 3 Clinical Study of GZR18 Injection for Weight LossRecruitingNCT07292441Phase 3
• Study of Pharmacokinetics and Safety of GZR18 Injection in Subjects With Liver Insufficiency and Normal Liver FunctionRecruitingNCT07144098Phase 1
• Study of Pharmacokinetics and Safety of GZR18 Injection in Subjects With Renal Impairment and Normal Renal FunctionRecruitingNCT07141030Phase 1
• Study on Gastric Emptying Effect and Drug-Drug Interactions of GZR18 InjectionRecruitingNCT07128888Phase 1
• A Phase I Study to Evaluate the PK and PD Profiles of GZR102 Injection Versus GZR4 Injection and GZR18 Injection Given Separately in Chinese Adult Overweight SubjectsNot yet recruitingNCT06974487Phase 1
• A Phase I Clinical Study to Evaluate the Effect of GZR18 Injection on the Pharmacokinetics of Oral Metformin Hydrochloride Tablets in Overweight/Obese SubjectsNot yet recruitingNCT06670209Phase 1
• The Study of [14C] GZR18CompletedNCT07119450Phase 1
• Efficacy and Safety of GZR18 Every 2 Weeks Versus Tirzepatide and Placebo in Obese or Overweight ParticipantsCompletedNCT06737042Phase 2
• A Phase III Clinical Study to Evaluate the Efficacy and Safety of GZR18 Injection in Adult Obese/Overweight SubjectsActive, not recruitingNCT06728124Phase 3
• A Phase I Study of GZR18 Injection in Healthy SubjectsCompletedNCT06548997Phase 1
• A Phase I Study of GZR18 Injection in Obese/Overweight SubjectsCompletedNCT06548945Phase 1
• A Study of GZR18 Injection in Obese/Overweight PatientsCompletedNCT06256562Phase 2
• A Study of GZR18 Injection in Chinese Obese/Overweight PatientsCompletedNCT06256536Phase 1/2